Paradigm changes and the future of HIV vaccine research: A summary of a workshop held in Baltimore on 20 November 2013

Journal of AIDS and Clinical Research

Volumn 5, Issue 3, 2014, Pages

  Van Regenmortel, Marc H V ^a   Andrieu, Jean Marie ^b   Dimitrov, Dimiter S ^c   Ensoli, Barbara ^d   Hioe, Catarina E ^e   Moog, Christiane ^a   Ruprecht, Ruth M ^f  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c NATIONAL CANCER INSTITUTE   (United States)

^d National AIDS Center   (Italy)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Antibody maturation; HIV vaccines; Immunogenicity; Paradigms; Research funding; Reverse vaccinology; Tat vaccine

Indexed keywords

EID: 84898876770     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000281     Document Type: Review

References (27)

1. Kuhn TS (1962) The Structure of Scientific Revolutions. University of Chicago Press.
2. Esparza J (2013) What has 30 years of HIV research taught us? Vaccines 1: 513-526.
3. Van Regenmortel MHV (2011) Limitations to the structure-based design of HIV-1 vaccine immunogens. J MolRecogn 24: 741-753.
4. Van Regenmortel MHV (2012) An Introduction to the current state of HIV vaccine research. J AIDS Clinic Res S8: e001.
5. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, et al. (2012) A blueprint for HIV vaccine discovery. Cell Host Microbe 12: 396-407.
6. Esparza J (2013) A brief history of the global effort to develop a preventive HIV vaccine. Vaccine 31: 3502-3518.
7. Van Regenmortel MHV (2012) Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch Virol 157: 1-20.
8. Mc Elrath MJ, Haynes BF (2010) Induction of immunity to human immunodeficiency virus type 1 by vaccination. Immunity 33: 542-554.
9. Virgin HW, Walker BD (2010) Immunology and the elusive AIDS vaccine. Nature 464: 224-231.
10. Bush V (1945) Science-The Endless Frontier: A Report to the President on a Program for Hostwar Scientific Research. Washington: National Science Foundation.
11. Stokes DE (1997) Pasteur's Quadrant. Basic Science and Technological Innovation. Brooking Institution Press, Washington, DC.
12. Esparza J (2005) The global HIV vaccine enterprise. International Microbiology 8: 93-101.
13. Mokyr J (2002) Technology and the Problem of Human Knowledge. In: The Gifts of Athena. Historical origins of the Knowledge Economy. Princeton University Press, Princeton, 1-27.
14. Hacking I (1983) Representing and Intervening. Cambridge University Press, Princeton.
15. Van Regenmortel MHV (2012) Basic research in HIV vaccinology is hampered by reductionist thinking. Front Immunol 3: 194.
16. Burton DR (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2: 706-713.
17. Van Regenmortel MHV (2011) Two meanings of reverse vaccinology and the empirical nature of vaccine science. Vaccine 29: 7875.
18. Dimitrov DS (2010) Therapeutic antibodies, vaccines and antibodyomes. Mabs 2: 347-356.
19. Bachler BC, Humbert M, Palikuqi B, Siddappa NB, Lakhashe SK, et al. (2013) Novel biopanning strategy to identify epitopes associated with vaccine protection. J Virol 87: 4403-4416.
20. Watkins JD, Sholukh AM, Mukhtar MM, Siddappa NB, Lakhashe SK, et al. (2013) Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS 27: F13-F20.
21. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, et al. (2011) Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34: 269-280.
22. Lu W, Chen S, Lai C, Guo W, Fu L, et al. (2012) Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Reports 2: 1736-1746.
23. Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, et al. (2010) Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS ONE 5: e13540.
24. Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, et al. (2012) HIV-1 Tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes with neutralization by anti-HIV antibodies. PLoS ONE 7: e48781.
25. Cafaro A, Caputo A, Fracasso C, Maggiorella M T, Goletti D, et al. (1999) Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 5: 643-650.
26. Cafaro A, Bellino S, Titti F, Maggiorella M T, Sernicola L, et al. (2010) Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in Mauritian Cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P. J Virol 84: 8953-8958.
27. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143-155.